Spots Global Cancer Trial Database for egfr t790m
Every month we try and update this database with for egfr t790m cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer | NCT03861156 | Solid Tumor NSCLC EGFR T790M | D-0316 | 18 Years - | InventisBio Co., Ltd | |
| Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC | NCT03543683 | Non-Small Cell ... Non-small Cell ... EGFR T790M | Osimertinib Aspirin | 18 Years - 75 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC) | NCT03532698 | Non-Small Cell ... Non-small Cell ... EGFR T790M | Aspirin Osimertinib | 18 Years - 75 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Lazertinib 160mg in EGFR T790M NSCLC | NCT05701384 | Lung Cancer Sta... EGFR T790M | Lazertinib | 19 Years - | Samsung Medical Center | |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | NCT03333343 | EGFR-mutant Non... | EGF816 trametinib ribociclib LXH254 INC280 gefitinib | 18 Years - | Novartis | |
| Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer | NCT04592666 | Lung Cancer, No... EGFR T790M EGFR Gene Mutat... | Almonertinib Pemetrexed Carboplatin | 18 Years - 75 Years | Fudan University | |
| Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC | NCT04105153 | EGFR Positive N... | 18 Years - | Thoraxklinik-Heidelberg gGmbH | ||
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | NCT04862780 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla... | BLU-945 osimertinib | 18 Years - | Blueprint Medicines Corporation | |
| Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) | NCT03810066 | NSCLC EGFR T790M FDG-PET | Osimertinib | 18 Years - | University Hospital, Essen | |
| Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer | NCT05377788 | Metastatic Lung... EGFR T790M | Lazertinib | 19 Years - | Samsung Medical Center | |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | NCT03333343 | EGFR-mutant Non... | EGF816 trametinib ribociclib LXH254 INC280 gefitinib | 18 Years - | Novartis | |
| Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC | NCT05458726 | EGFR T790M Osimertinib Non-small Cell ... ddPCR | Osimertinib | 18 Years - 75 Years | Peking Union Medical College | |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | NCT04862780 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla... | BLU-945 osimertinib | 18 Years - | Blueprint Medicines Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
